Literature DB >> 501817

Experience with flutamide in previously untreated patients with advanced prostatic cancer.

P C Sogani, W F Whitmore.   

Abstract

Twenty-one patients with advanced prostatic adenocarcinoma previously untreated with conventional endocrine therapy were treated with an oral non-steroidal antiandrogen, flutamide. There were 19 favorable responders, 1 failure and 1 equivocal response. Flutamide seems to be a safe antiandrogen, which is effective in the management of previously untreated patients with advanced prostatic carcinoma.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 501817     DOI： 10.1016/s0022-5347(17)56539-8

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  8 in total

1.  Flutamide--an antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency.

Authors:  B Stegmayr; J E Johansson; L B Schnürer
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 2.  Update in cancer chemotherapy: genitourinary tract cancer, Part 3: Cancer of the prostate.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-03       Impact factor: 1.798

3.  Iatrogenic damage to male reproductive function.

Authors:  W F Hendry
Journal:  J R Soc Med       Date:  1995-10       Impact factor: 5.344

Review 4.  Antiandrogens in prostate cancer.

Authors:  P Reid; P Kantoff; W Oh
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.

Authors:  Antonella Pepe; Michael Pamment; Yeong Sang Kim; Sunmin Lee; Min-Jung Lee; Kristin Beebe; Anton Filikov; Len Neckers; Jane B Trepel; Sanjay V Malhotra
Journal:  J Med Chem       Date:  2013-10-30       Impact factor: 7.446

6.  Advances in the treatment of metastatic prostatic cancer.

Authors:  J S Elder; R P Gibbons
Journal:  West J Med       Date:  1985-09

7.  The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.

Authors:  M Schulz; A Schmoldt; F Donn; H Becker
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Temporary prostatic stenting and androgen suppression: a new minimally invasive approach to malignant prostatic retention.

Authors:  K M Anson; D G Barnes; T P Briggs; G M Watson; R A Miller
Journal:  J R Soc Med       Date:  1993-11       Impact factor: 18.000
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.